Loading
Instead of making cell therapy from each patient's own cells in a factory, inject a particle that reprograms immune cells inside the body, made in bulk, so a dose costs thousands rather than hundreds of thousands.
Autologous CAR-T costs hundreds of thousands of dollars and weeks of manufacturing per patient, restricting it to a small fraction of eligible patients in rich countries. In vivo CAR generation with lipid nanoparticles or targeted lentiviral vectors (Umoja, Interius, Orna and others) has entered the clinic in B-cell malignancies. The proposal is a coordinated programme to develop an in vivo CD19 or BCMA product with a manufacturing process and cost-of-goods target under $5,000 per dose, licensed for distribution through generic-style manufacturers in middle-income countries, with regulatory pathways agreed in advance.
One of the most cited reviews Europe PMC returns for BCMA in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD19 in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for CD19 in Multiple myeloma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Interius BioTherapeutics, Umoja Biopharma, Orna Therapeutics (Eli Lilly), In vivo CAR-T against solid-tumour antigens.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, BCMA, Manufacturing cost and time for living and radioactive medicines, CD19.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy, Manufacturing cost and time for living and radioactive medicines, Most of the world has almost no cancer care, CAR-T cell therapy.
Shares BCMA, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
Shares In vivo CAR-T, BCMA, CD19, Multiple myeloma.
Shares BCMA, CD19, CAR-T cell therapy, Multiple myeloma.